TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02964858

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard Arm
Description: Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT , CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental Arm
Description: Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT,CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
Study: NCT03498937

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: 10 active tDCS sessions (2 sessions/day for 5 days, 30 min each, 2 mA) applied to the dlPFC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: 10 sham tDCS sessions (2 sessions/day for 5 days, 30 min each, 0 mA) applied to the dlPFC

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: 10 sham tDCS sessions (2 sessions/day for 5 days, 30 min each, 0 mA) applied to the dlPFC
Study: NCT02763501

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closure of mesenteric defects
Description: Closure of mesenteric defects by use of non-absorbable running sutures in RCT; and according to the choice of the surgeon in the non-RCT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: closure of mesenteric defects
Description: Closure of mesenteric defects by use of non-absorbable running sutures in RCT; and according to the choice of the surgeon in the non-RCT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-closure of mesenteric defects
Description: Mesenteric defects are left open

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-closure of mesenteric defects
Description: Mesenteric defects are left open
Study: NCT00770835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and Metformin
Description: Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glibenclamide and Metformin
Description: Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.
Study: NCT02121496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resources for Postpartum Parenting
Description: The intervention includes four-sessions that targets maternal caregiving of young infants to increase infant sleep and reduce fuss/cry behavior and thereby simultaneously consolidate women's enjoyment of and confidence in their maternal role, this, in turn, promotes a cycle of a mutually re- warding engagement in the mother-infant dyad - the antithesis of a 'toxic' experience, and a strong foundation for improving the chances of a successful psychosocial adjustment, including adequate employment. Investigators believe PREPP holds tremendous promise as an intervention to fill the science-practice gap in the promotion of an optimal emotional environment for the developing infant, particularly for women and children living in poverty and/or facing significant psychosocial hardship.
Study: NCT02079012

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10-week walking program
Study: NCT04293289

Intervention type: OTHER
Group type: OTHER
Intervention: CICS-1 (investigational device),SPM-011(investigational drug)
Description: Intravenous administration of SPM-011 and neutron irradiation with CICS-1.
Study: NCT01559194

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat Diet plus exercise
Description: Low fat diet plus exercise - Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Carbohydrate diet + Exercise
Description: Low carbohydrate diet plus exercise: Subjects were educated about a low carbohydrate diet and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
Study: NCT02383589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil Placebo
Description: MMF matching placebo will be administered orally Q12H.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: MMF will be administered at a starting dose of 500 milligrams (mg) Q12H and the dose will be titrated to achieve a goal of 1 gram (gm) Q12H.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at a dose of 1000 mg via IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab Placebo
Description: Rituximab matching placebo will be administered via IV infusion.
Study: NCT02795416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab Cosentyx TM
Description: Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.~First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month
Study: NCT00007813

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT04411927

Intervention type: OTHER
Intervention: assessment of postural stability
Description: assessment of postural stability

Intervention type: OTHER
Intervention: assessment of postural stability
Description: assessment of postural stability

Intervention type: OTHER
Intervention: assessment of postural stability
Description: assessment of postural stability
Study: NCT00591825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-cycloserine
Description: D-cycloserine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: D-cycloserine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04118517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Using intrinsically labelled bean protein to assess bioavailability of amino acids in healthy adults
Description: The intervention comprises a test meal of intrinsically deuterium labelled stewed common bean with rice. The meal is mixed with a reference protein (Universally labelled 13C-spirulina, 12 mg/kg) and 13C6-Phenylalanine (0.05mg/kg) which is divided into equal mini meals and fed hourly over 8 hours. Protein in the total meal provides 15% of the energy intake with the labelled bean contributing \>50% of the protein.
Study: NCT02592018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.
Study: NCT04376060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gen-Os®; The soft lamina (OsteoBiol®)
Description: The xenograft used in this study was the Gen-Os® by OsteoBiol; as described by the manufacturer, it is a carbonated nanocrystal bone mineral and collagen of natural heterologous origin, obtained by the treatment of cortical bone tissue of equine origins. Its granulometry ranges between 0.25 to 1 mm and it is described as being slightly radiopaque.~The soft lamina (OsteoBiol®) used is a 35x35mm medium curved membrane of porcine origins. Its clinical indications as described by the fabricator: a co-adjuvant for the reconstruction or the partial or complete recovery of lost bone portions, fillers of non-infected, non-sclerotic and well blood bedewed bone defects.
Study: NCT01802489

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule identical in appearance to Amiloride 10mg capsule
Study: NCT04412538

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Description: Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule
Description: Two doses of low dosage(50U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Description: Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule
Description: Two doses of medium dosage(100U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Description: Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule
Description: Two doses of high dosage(150U/0.5ml) Inactivated SARS-CoV-2 Vaccine at the vaccination schedule of day 0,14

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on a 0- and 28-day schedule
Description: Two doses of placebo at the vaccination schedule of day 0,28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on a 0- and 14-day schedule
Description: Two doses of placebo at the vaccination schedule of day 0,14
Study: NCT02196623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic exercise
Description: Supervised, progressive aerobic exercise program for 8 weeks under hypoxic conditions

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normoxic Exercise
Description: Supervised, progressive aerobic exercise program for 8 weeks under normoxic conditions
Study: NCT03882710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol XR
Description: Metoprolol XR capsule 25/50/100 mg once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoprolol XR
Description: Metoprolol XR capsule 25/50/100 mg once daily for 12 weeks
Study: NCT00668031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trasylol (Aprotinin, BAYA0128)
Description: A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of aprotinin using an IV infusion pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of of placebo using an IV infusion pump
Study: NCT01557179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalofemme
Description: The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Estriol cream (Ovestin)
Description: The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
Study: NCT02072928

Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.
Study: NCT02427880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide and Hydrochlorothiazide Followed by Furosemide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide and Hydrochlorothiazide Followed by Furosemide
Study: NCT01768650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management #1
Description: Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management #2
Description: Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
Study: NCT00165256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Wide excision of DCIS and a minimum of 1cm histologically negative margin of breast tissue
Study: NCT00450216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen/famotidine
Description: HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 800mg administered orally 3 times daily for 24 weeks
Study: NCT03518554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3068
Description: JAB-3068 will be orally administered on a daily basis. Patients need to fast 2 hours before （6 hours for PK days) and 2 hours after each dosing.
Study: NCT00184236

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multitreatment approach
Description: 12 months regimen consisting of group meetings every 2 weeks involving a physician, psychologist, physiotherapist and clinical nutritional physiologist. 21 h treatment during the first 3 months: 3 activity sessions (3 h) and 3 group conversations (4 h). Attendance inclusion criterium was set to minimum of 80%

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic interval training
Description: Walking/running 'uphill' on a treadmill twice a week for 3 months. 10 min warming-up at 70% of Hfmax before performing 4x4 intervals at 90-95% of Hfmax. 3 min active recovery at 70% of Hfmax between each interval. 5 min cool-down period, giving a total of 40 min.
Study: NCT02909985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tungsten halogen light with narrow bandpass filters
Description: As intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band tungsten halogen light source that passes through narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tungsten halogen light with narrow bandpass filters
Description: As intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band tungsten halogen light source that passes through narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see.
Study: NCT01434251

Intervention type: OTHER
Group type: OTHER
Intervention: Anti-hypotensive treatment
Description: Hypotension is managed using a variety of treatment options. Options include: fluid bolus(es), dopamine, dobutamine, hydrocortisone and epinephrine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anti-hypotensive treatment
Description: Hypotension is managed using a variety of treatment options. Options include: fluid bolus(es), dopamine, dobutamine, hydrocortisone and epinephrine.
Study: NCT01500850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nph insulin
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human insulin
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~human insulin: bolus injections before each main meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human insulin
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~human insulin: bolus injections before each main meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~Insulin glulisine: bolus injections before each main meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Description: Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.~Insulin glulisine: bolus injections before each main meal
Study: NCT03024476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intensification
Description: Suggested algorithm for behavioral intensification:~* If frequency of BP measurement ≤5 in a week, send a texting message~* If frequency of BP measurement ≤3 in a week, make a telephone contact by research nurse~* Target range of home-systolic blood pressure: 110 - 135~* If rate of outlier exceeds 50% in a week (based on ≥5 measurements in a week), make a telephone contact by research nurse (applied at least 2 weeks after randomization). A call for breakthrough visit may be issued when clinically required (decided by the institutional investigator)~* If frequency of BP measurement ≥ 10 in a week and frequency of outlier = 0 in a week, send a texting message to encourage and compliment on excellent BP management

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological intensification based on olmesartan
Description: * Study drug will be provided from the roll-in period.~* Step I:~  * Use olmesartan 20 mg only if mean systolic blood pressure ≤150 mm Hg during the immediate past 2 days~ * Use olmesartan 40 mg if mean systolic blood pressure \>150 during the immediate past 2 days~* Step II: olmesartan 20 mg or 40 mg + amlodipine 5 mg~* Step III: olmesartan 20 mg or 40 mg + amlodipine 10 mg~* Step IV: olmesartan 20 mg or 40 mg + amlodipine 10 mg + hydrochlorothiazide 12.5 mg~* If blood pressure profile showed high degree variability to evoke clinical concern, consider discontinuation of hydrochlorothiazide or reduction of olmesartan dose.~* Use of beta-blockers is permitted if clinically indicated.~* At each clinic visit regardless of regular or breakthrough visit, follow the pharmacological intensification rule.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bluetooth-equipped sphygmomanometer
Description: * Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. (Identical for both intervention and control groups)~* Every blood pressure and heart rate measured will be encrypted and stored in the main server. (Identical for both intervention and control groups)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bluetooth-equipped sphygmomanometer
Description: * Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. (Identical for both intervention and control groups)~* Every blood pressure and heart rate measured will be encrypted and stored in the main server. (Identical for both intervention and control groups)
Study: NCT03746951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hcl 0.5% Inj Vil 20Ml
Description: Anesthetic agent used in peripheral nerve block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hcl 0.5% Inj Vil 20Ml
Description: Anesthetic agent used in peripheral nerve block
Study: NCT02901873

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Impedance Spectroscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Impedance Spectroscopy